Abstract
Infants and children have historically received a weight-based escalating defibrillation dose, commencing at 2J/kg. Researchers are increasingly suggesting that 2J/kg maybe an ineffective initial defibrillation dose. However without a definitive study there has been hesitancy to modify this initial dose. The International Liaison Committee on Resuscitation made a recommendation in 2010 of an initial dose of 2–4 J/Kg, increased from 2 J/Kg. The American Heart Association and the European Resuscitation Councils now have different initial dosing recommendations for children. The ERC advocates 4J/kg as the initial dose without escalation for subsequent shocks, while the AHA recommends 2–4 J/Kg, increasing to ≥ 4 J/Kg with subsequent shocks up to adult dose. The difficulty of finding a dose based on robust evidence continues to provide a stimulus for research to better define the best defibrillation energy dose for children.
Keywords: Arrest, defibrillation, child, countershock, resuscitation.
Current Pediatric Reviews
Title:Defibrillation in Children: Why a Range in Energy Dosing?
Volume: 9 Issue: 2
Author(s): Jonathan Egan and Dianne L. Atkins
Affiliation:
Keywords: Arrest, defibrillation, child, countershock, resuscitation.
Abstract: Infants and children have historically received a weight-based escalating defibrillation dose, commencing at 2J/kg. Researchers are increasingly suggesting that 2J/kg maybe an ineffective initial defibrillation dose. However without a definitive study there has been hesitancy to modify this initial dose. The International Liaison Committee on Resuscitation made a recommendation in 2010 of an initial dose of 2–4 J/Kg, increased from 2 J/Kg. The American Heart Association and the European Resuscitation Councils now have different initial dosing recommendations for children. The ERC advocates 4J/kg as the initial dose without escalation for subsequent shocks, while the AHA recommends 2–4 J/Kg, increasing to ≥ 4 J/Kg with subsequent shocks up to adult dose. The difficulty of finding a dose based on robust evidence continues to provide a stimulus for research to better define the best defibrillation energy dose for children.
Export Options
About this article
Cite this article as:
Egan Jonathan and Atkins Dianne L., Defibrillation in Children: Why a Range in Energy Dosing?, Current Pediatric Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573396311309020006
DOI https://dx.doi.org/10.2174/1573396311309020006 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry The Cellular and Molecular Basis of Health Benefits of Grape Seed Proanthocyanidin Extract
Current Pharmaceutical Biotechnology Neurologic Sequelae in Critical Illness: Evaluation and Outcomes
Current Respiratory Medicine Reviews Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Effect of Ouabain on the Immune System
Current Hypertension Reviews The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology New Drugs for Epidural Analgesia
Current Drug Targets Replicative Senescence: The Final Stage of Memory T Cell Differentiation?
Current HIV Research Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Estrogen Regulation of MicroRNA Expression
Current Genomics Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Critical Issues in Delivery of RNAi Therapeutics In Vivo
Current Pharmaceutical Biotechnology Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research